87 results
424B5
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Prospectus supplement for primary offering
4:52pm
include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements … of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and shows potential for the treatment of hepatocellular carcinoma
8-K
EX-99.1
uimaigkr
24 Jul 23
Regulation FD Disclosure
4:04pm
424B5
mrff 4jwf
21 Jul 23
Prospectus supplement for primary offering
4:39pm
8-K
EX-99.1
o73rbe3 9h
22 May 23
Regulation FD Disclosure
1:05pm
8-K
EX-99.1
wf52 mrj5bu
17 Oct 22
Regulation FD Disclosure
5:13pm
8-K
EX-99
e95g2rp35l zrypysp
21 Dec 21
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
8:25am